DPP-4 inhibitor administration has yielded mixed results in treating patients with CAD and heart failure in both pre-clinical and clinical studies, with many clinical studies showing no significant change in cardiovascular mortality or related complications [5–11]. This evidence concerns the gene DPP4 and heart failure.